WET AGE-RELATED MACULAR DEGENERATION
DIABETIC MACULAR EDEMA
DIABETIC RETINOPATHY
NON-INFECTIOUS UVEITIS
DRY AGE-RELATED MACULAR DEGENERATION
RETINAL VEIN OCCLUSION
ADDITIONAL INFORMATION
MK-8748-002 Malbec Study (St Pete and North Tampa) – A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2mg) in subjects with neovascular age-related macular degeneration (NVAMD)
KSMP002-S1 Alto Study – A Randomized, Double-masked, Active-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Tedromer 5 mg Compared with Intravitreal Aflibercept 2 mg in Participants with Visual Impairment Secondary to Diabetic Macular Edema
GR46431 Study (Gated Study) – A PHASE I, MULTICENTER, OPEN-LABEL, MULTIPLE-ASCENDING DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF RO7823653 ADMINISTERED BY INTRAVITREAL INJECTION AS MONOTHERAPY AND IN COMBINATION WITH FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA
MK-8748-004 Sangiovese Study (North Tampa) – A Randomized, Double-Masked, Multicenter, 3-Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Diabetic Macular Edema
MK-8748-005 Syrah Study (Starting in September-October) – A Randomized, Double-Masked, Multicenter, 3-Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Diabetic Macular Edema
4D-150-C005 Study (Starting in September) – A Phase 3, Randomized, Double-Masked, Active-Controlled Trial to Evaluate the Efficacy, Safety, and Durability of a Single Intravitreal Injection of 4D-150 versus Aflibercept in Adults with Diabetic Macular Edema (4SIGHT)
No studies enrolling now
KSMP001-01-S1 Peak Study – A Multicenter Platform Study on the Safety, Tolerability, Bioactivity, and Pharmacokinetics of Intravitreal Therapies in Retinal Vascular and Inflammatory Diseases
KSMP001-02-S2 Pinnacle Study – A Multicenter Platform Study on the Safety, Tolerability, Bioactivity, and Pharmacokinetics of Intravitreal Therapies in Retinal Vascular and Inflammatory Diseases
R3918-AMD-2326 Sienna Study – A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration
GR44351 GAllette Study (Starting in September/October) – A Phase IIa, Multicenter, Open-Label, Single-arm Study to Optimize Subretinal Delivery and to Evaluate Safety and Activity of OpRegen in Patients with Genographic Atrophy Secondary to Age-Related Macular Degeneration
APL3007-GA-201 Study (St. Pete and North Tampa) – Phase 2, Randomized, Placebo-Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration
DFI18231 Study – A Phase 1/2, study to evaluate the safety, tolerability, and efficacy of one-time intravitreal dose of SAR446597 in participants with geographic atrophy secondary to age-related macular degeneration
CFWY003A12201 Circle Study – A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration
No studies enrolling now
PI Crane: Retina Vitreous Associates of Florida – Tampa, FL
Public Minutes Link: https://ibcminutes.com/FL00640
PI Eichenbaum: Retina Vitreous Associates of Florida – St. Petersburg, FL
Public Minutes Link: https://ibcminutes.com/FL00155